EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC

Ali Salanti

Bioconjugate Insights · 24.03.2026 · 1 (2) · 75–79

DOI: 10.18609/bci.2026.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 24.03.2026. Verfasst von Ali Salanti. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“We recently obtained the first data ... which demonstrates that the antibody reaches the tumors to a significant extent with very limited off-target binding.”Lauren Coyle, Editor, Bioconjugate Insights, speaks with Ali Salanti, Professor, University of Copenhagen, and CEO, Var2 Pharma, about the development of a new monovalent ADC with broad anti-tumor activity – from a serendipitous discovery to preparing for clinical trials.

Zitieren

APA

Salanti, A. (2026). From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC. Bioconjugate Insights, 1(2), 75–79. https://doi.org/10.18609/bci.2026.011

Vancouver

Salanti A. From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC. Bioconjugate Insights. 2026;1(2):75–79. doi:10.18609/bci.2026.011

BibTeX
@article{Salanti2026,
  author = {Salanti, Ali},
  title = {From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC},
  journal = {Bioconjugate Insights},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {75–79},
  doi = {10.18609/bci.2026.011}
}
Kostenlos starten →